SEC Form 4 · accession 0001144204-17-065040
Eloxx Pharmaceuticals, Inc. · ELOX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Gregory L Weaver
Officer — Chief Financial Officer
Period of report
Dec 20, 2017
Accepted (ET)
Dec 22, 2017 · 2:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001035354
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $7.00 | Dec 20, 2017 | A | 399,266 | A | — | Dec 20, 2027 | Common Stock | 399,266 | 399,266 | D |
Explanation of responses
- F1The option vests and becomes exercisable over a four-year period commencing on December 20, 2017, with one fourth of the shares of common stock underlying the options vesting on December 20, 2018, and the remainder vests in twelve equal quarterly installments thereafter.